EULAR 2020: Lilly's Taltz(r) (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis

MLA

“EULAR 2020: Lilly’s Taltz(r) (Ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis.” Plus Company Updates, 4 June 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.625759430&authtype=sso&custid=ns315887.

APA

EULAR 2020: Lilly’s Taltz(r) (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis. (2020, June 4). Plus Company Updates.

Chicago

Plus Company Updates. 2020. “EULAR 2020: Lilly’s Taltz(r) (Ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis,” June 4. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.625759430&authtype=sso&custid=ns315887.